Skip to content

Pentadeca Arginate dosage and evidence

Written by Reviewed Sep 2026

Animal or lab only. Only animal or lab studies on this page. No study in people yet. 1 animal study, no human study.8 reported

The short answer

Pentadeca arginate is BPC-157 with a different salt. The 15 building blocks are the same. It was made to get around compounding rules. It has no studies of its own, so it borrows BPC-157's evidence, which is almost all animal work.

Evidence grade for Pentadeca Arginate: Animal or lab only. The rule: only animal or lab studies on this page. No study in people yet. The sum on this page: 1 animal study, no human study. A grade counts how much has been done to people, not whether it works.

People given it
0
Human studies
0
Found nothing
0

Dose

No human dose established

No published study on this page has given this compound to people and reported a result.

1 animal study, no human study

8 effects reported, 5 unwanted, 3 wanted, by people using it, not a trial

Goal pages: Injury, healing and recovery

In plain English

In plain English, from Aaron

This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.

Pentadeca Arginate is BPC-157 under a new name. It is the same 15 piece chain of amino acids with a different salt attached. Sellers made it after the FDA put BPC-157 on a compounding watch list in 2023. They sell it as a legal, more stable version. Neither claim has been shown or accepted by the FDA. It is not approved anywhere.

What people take it for

  • Everything people take BPC-157 for: tendons, joints, muscle tears and gut trouble.
  • A legal way to keep getting BPC-157 after their clinic stopped offering it.
  • A more stable version that lasts longer in the vial.
  • Some people believe it is a new and better peptide. It is not new.

What studies in people showed

There are no studies of Pentadeca Arginate. None in mice. None in people. Not one paper has tested whether the new salt changes how it absorbs, how long it lasts, or what it does. Every study you will see quoted for it was done on BPC-157. So read the BPC-157 page. The short version: hundreds of rat and mouse studies, and a tiny human record with no study of the shot people buy. The safety study on this page gave BPC-157 to rats and dogs and found no harm at the doses tested. That is animals, not people. One more thing. The legal pitch is out of date. The FDA took BPC-157 off that list in April 2026. In July 2026 a panel voted to let pharmacies compound it. That vote is advice, not approval. But the reason this product exists has mostly gone away.

What people report

Reports, not study results

The good

  • The same reports as BPC-157: less pain in the first week or two, and a tendon or joint that puts up with more work by week three to six.
  • Some people say the vial holds up longer at room temperature. Nobody has tested that.
  • Clinics that dropped BPC-157 kept offering this, so people could keep their protocol going.

The bad

  • No effect at all. Same as BPC-157, this is a common report.
  • Red, sore or lumpy spots where the needle went in.
  • Nobody knows what months of use does. No study has looked at either version.
  • You are paying more for the same molecule with a new label.
  • Not knowing what is in the vial. The name has no FDA definition, so a seller can put anything under it.

Where these come from: There is no trial of this product, so there are no trial reports. Everything above is from peptide forums such as r/peptides, from clinic write ups, and from the BPC-157 record on this site. People logging PDA and people logging BPC-157 describe the same things, which makes sense, since it is the same peptide.

My bottom line

This is BPC-157 with a marketing wrapper. It has zero data of its own and rides on the animal work of the parent. Everything I said on the BPC-157 page applies here, plus a markup. I would not buy it.

An opinion, not a finding. I am a coach, not a doctor.

What it has been measured to do

Nothing indexed yet

The 6 citations on this page do not report a result for any of the 36 goals indexed here. Most of what sits here is something else: a listing of a planned study, a study of how the body handles the drug, a safety report or a government record. None of those tests whether it works.

Show full evidence

What is Pentadeca Arginate?

Pentadeca arginate is BPC-157 with a different salt. The 15 building blocks are the same. It was made to get around compounding rules. It has no studies of its own, so it borrows BPC-157's evidence, which is almost all animal work.

Pentadeca arginate showed up after the FDA put BPC-157 in Category 2 of its compounding list in 2023. Its peptide chain is exactly the same as BPC-157. Only the salt it is packed with is different. Sellers say it keeps better and is legally different. Neither claim has been published or accepted by the FDA. A 2025 review found the whole human record for BPC-157 is one report on 12 patients, with no one to compare them against. BPC-157 came off Category 2 in April 2026, and an FDA advisory committee voted for it in July 2026. That makes the legal alternative pitch pointless.

How does Pentadeca Arginate work?

Assumed to work the same way as BPC-157. In animals, BPC-157 seems to help grow new blood vessels and repair tissue.

What have studies in people found about Pentadeca Arginate?

Nothing has been measured under this name, in people or in any animal. There is no published study of pentadeca arginate in any species, no registered trial, and no PubMed record under any name it is sold as. Every number a seller quotes for it came from studying a different salt form of the same peptide.

  • PubMed finds zero records for pentadeca arginate, zero for pentadecapeptide arginate, and zero for BPC-157 arginate. No paper is about this product.
  • ClinicalTrials.gov finds zero studies of pentadeca arginate, by name or on a general search.
  • No regulator has reviewed it. FDA's safety page on compounding substances, updated 22 April 2026, does not name it. FDA's July 2026 advisory meeting on pharmacy compounding looked at two forms of BPC-157, the free base and the acetate, not the arginate.
  • No comparison exists. No study in any species has compared the arginate salt with the acetate salt on stability, absorption, blood levels, where it goes in the body, or effect. So the two sales claims, that it is more stable and that it is a different substance, have never been tested.
  • The evidence people quote belongs to BPC-157. FDA's July 2026 review of BPC-157 counted five studies in people, with fewer than 110 people in all. Two were only short conference summaries, none gave it for more than two weeks, and none used the shot under the skin that buyers use. A 2025 review that screened 544 records kept 36 studies, and 35 of them were animal or lab work.
  • Even for BPC-157 itself, there is almost no data on how the body handles it. A 2026 review in Pharmaceutics counted fewer than 30 people across three small studies with no comparison group, and no finished mid-stage study. It argued the block is missing drug development work, not missing biological activity.

What this does not tell you: There is no dose, no blood level, no half-life, no absorption figure and no result for this product in any species. Borrowing the BPC-157 record means assuming the salt makes no difference. That is probably true, and it is still untested. And the BPC-157 record being borrowed is itself almost all rodent work, with no shots under the skin in people at all. Anyone asking what pentadeca arginate does should know the honest answer: nobody has ever looked.

The state of the research

Pentadeca arginate is the clearest case in this group of a product born from a rule change, not a research finding. The honest way to tell it is in order.

In 2023, FDA put BPC-157 in Category 2 of its compounding list, which made it hard to sell through pharmacies. Pentadeca arginate appeared after that. Its peptide recipe, GEPPPGKPADDAGLV, is the same as BPC-157. What differs is the salt it comes with: arginine instead of acetate. The pitch was that it is more stable and legally different. Neither claim was published, neither was tested, and FDA never accepted the second one.

Then the reason it existed went away. FDA took BPC-157 out of Category 2 in April 2026. On 23 July 2026, FDA's advisory panel on pharmacy compounding voted 8 to 6, with one member not voting, to recommend BPC-157 for the compounding list, against the advice of FDA's own reviewers. Whatever happens next, the legal workaround that pentadeca arginate was built on is gone.

It is worth being exact about what kind of empty record this is, because it is not like the others in this group. KPV has no human data, but labs are actively studying the molecule in animals, and in cells. FOXO4-DRI has no human data, but it has a founding paper in the journal Cell and an outside repeat. Pentadeca arginate has a different salt. No lab is studying it, because there is nothing to study that is not already being studied as BPC-157. No company will ever pay to test a salt form of a peptide it cannot own. And no journal would publish a test that found no difference from the acetate.

So this is not an unfunded question staying open. The question is whether the arginate salt acts differently from the acetate salt. It has a likely answer that nobody bothered to check, and the product was sold on the guess that the answer was yes.

The evidence, in charts

Fig. 1a · how many people

0people have taken this in any study cited here

0 people · 0 studies in people

What this page cites instead is 1 animal study and 5 reviews. None of them gave the compound to a person.

Counted from the list of sources on this page. We draw this chart only when a study in people is cited. An empty one is the answer, not a gap in the page.

Fig. 1b · evidence mix

None of the 6 sources here are studies in people.

06 sources
  • Animal study · done in animals117%
  • Review of studies · sums up other studies583%

Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.

Fig. 2 · evidence over time

The studies cover 3 different years, 2020 to 2026, counted from the list of sources on this page.

Fig. 3 · legal status at a glance

Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.

Fig. 4 · how much does what

Nobody has tested different amounts in people

This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.

Waiting on a study nobody has runMaking one takes a study that gives different amounts to different groups of people and compares them. Nobody has paid for that for this compound.

Fig. 5 · what the molecule is

Kind of compound
Peptide
Molecule weight
1,419.5 Da for the BPC-157 pentadecapeptide it is based on; supplied as the arginate salt, which is heavier
Half-life
Stated in words, not a numbersee the exact wording below
Chain length
None on file

Half-life as stated on file: No human pharmacokinetics for either salt form

No amino acid sequence is on file for Pentadeca Arginate, so none is drawn rather than guessed from a name.

The studies we cite

Where to buy Pentadeca Arginate

5 sellers list Pentadeca Arginate in our latest read. They are ranked by trust score, then by archive rating, then by certificate tier, then by the lowest price per milligram. Archive evidence is counted before source-backed. Each path is out of 4, and the two are not added. A higher price does not raise the score. The letter is the certificate chip. 0 of them have a published certificate that names Pentadeca Arginate.

Some seller links may pay this site when you buy through them. A payment never changes a seller's tier or rank, and no seller has a say in any page.

SellerTrust scoreVial sizesFrom, per mgCertificate for Pentadeca ArginateSeller link
EZ Peptides
75 StrongSource-backed 4 of 4. Archive evidence 3 of 4.A
10 mg$4.40None found for Pentadeca ArginateView
Ameano Peptides
72 StrongSource-backed 4 of 4. Archive evidence 2 of 4.A
10 mg$4.40None found for Pentadeca ArginateView
Ion Peptide
60 FairSource-backed 2 of 4. Archive evidence 0 of 4.C
10 mg$4.90None found for Pentadeca ArginateView
ARG Peptides
35 WeakSource-backed 2 of 4. Archive evidence 2 of 4.B
10 mg$2.90None found for Pentadeca ArginateView
Nexa Peptide Store
18 InsufficientSource-backed 1 of 4. Archive evidence 1 of 4.C
10 mg$13.8None found for Pentadeca ArginateView
  • LC Lab-confirmed: the issuing laboratory echoed this certificate back
  • A Current certificate, independent laboratory named, laboratory not yet checked
  • B Certificate published, but no laboratory link, older than a year, or the laboratory did not recognise the published lookup
  • C No certificate could be read

Every listing and vial size for Pentadeca Arginate · How the trust score is counted

Sellers named on the price pages are ranked by certificate tier, then price, and any affiliate income is disclosed there. Naming a seller is not a recommendation to buy or use anything.

Common questions

Has Pentadeca Arginate been tested in people?

Not in any study cited here. Pentadeca arginate is BPC-157 with a different salt. The 15 building blocks are the same. It was made to get around compounding rules. It has no studies of its own, so it borrows BPC-157's evidence, which is almost all animal work.

What is the Pentadeca Arginate dosage?

No human dose established. No published study on this page has given this compound to people and reported a result. 1 animal study, no human study

Is Pentadeca Arginate FDA-approved?

Not approved; the FDA does not recognize it as a separate substance

Is pentadeca arginate different from BPC-157?

Chemically it is the same peptide with a different salt. No study shows it is absorbed, keeps, or works any differently.

Is it legal where BPC-157 is not?

The FDA has never backed that claim. Both are unapproved drugs when sold for people to use.

Latest reading on Pentadeca Arginate

Blog posts about Pentadeca Arginate, newest first.

Compare Pentadeca Arginate with

Pentadeca Arginate vs BPC-157Pentadeca Arginate vs TB-500Pentadeca Arginate vs GHK-Cu

Related compounds

BPC-157TB-500KPV